HTG Molecular Diagnostics today announced the availability of the qDiscovery miRNA Whole Transcriptome Array (WTA) Version 16, a complete solution for microRNA (miRNA) analysis on any sample type or size.
This array is an update to the previous Version 11 which measures all known human, rat and mouse miRNA in a single sample well with a quality control tested list of available miRNA genes. It also includes 35 of the top endogenous housekeeping mRNA genes for data normalization. The product is based on HTG's proven qNPA ArrayPlate technology platform, which allows researchers to measure miRNA and mRNA simultaneously in the same sample well, simplifying studies involving both micro and messenger RNA.
HTG's extraction-free qNPA technology provides customers with access to all soluble and insoluble miRNA which allows for usable data from very small sample sizes. Customers have the option to simply lyse cell samples or submit samples to HTG's service facility for processing where the samples are processed and data normalized before being returned to the customer for analysis.
"The update to this miRNA screening product shows HTG's continued commitment to advancing the field of miRNA research," said BJ Kerns, senior vice president, Companion Diagnostics and Strategic Marketing, HTG Molecular Diagnostics. "The technology behind the miRNA WTA v16 provides researchers with reproducible and affordable answers to successful signature biomarker discovery programs. We are pleased to offer customers this updated, accurate and reliable solution for miRNA screening."
HTG's qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development. HTG's platform is highly flexible and designed for high throughput automation; it allows scientists to test any sample, including fixed tissues, without RNA extraction or target amplification. The technology is ideal for detecting small yet important changes in gene expression levels which other gene expression platforms cannot reliably detect.
Epigenetic silencing of BEND4 unveils new path for PDAC treatment